DH

DH is a classic distressed-value puzzle: a 76%-gross-margin software business priced like it's going out of business (0.3x sales, $75M cap), yet it threw off $53.8M of operating cash flow and ~$37M of free cash flow in FY2025. With $164M cash against ~$165M total debt, the balance sheet is roughly net-cash-neutral, so the equity is effectively trading at ~2x cash generation. Management is leaning into that gap — $49.5M of buybacks (up 121% YoY) at depressed prices shrank the share count 7.5%, which is accretive if the cash flow holds. On the cash-flow lens alone, this is cheap.

The problem is the lens the rubric weighs most heavily: durable, profitable growth — and DH has the opposite. Revenue fell 4.2% to $242M and gross profit fell faster, down 7.2%, meaning even gross margin is eroding. For a subscription 'healthcare commercial intelligence' platform whose own glossary leans on ARR and Net Dollar Retention, shrinking top-line is the tell that NDR has likely slipped below 100% — a melting-ice-cube dynamic that the 2x FCF multiple may be correctly, not foolishly, pricing. The GAAP record is brutal: net losses of -$202M, -$413M and -$139M the last three years and a -$780M accumulated deficit, dominated by goodwill impairments that confirm the Advent-era valuation was badly overstated. Total assets dropped 32.5% in a year — that's the write-down machine still running.